PAX2 Inhibition Induces DEFB1-Mediated Prostate Cancer Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer chemotherapies based on alkylating agents, anti-metabolites, and natural products often cause severe side effects and toxicity due to their heterogeneous mechanisms of action, affecting both cancer cells and normal cells.
Innovation Solution
The use of human beta defensin-1 (DEFB1) to induce prostate cancer tumor immunity by inhibiting the transcriptional repressor PAX2 through siRNA therapy or small molecules that block PAX2 expression, allowing DEFB1-mediated cell death and triggering an immune response specifically against prostate cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticancer chemotherapies (alkylating agents, anti-metabolites, natural products) are used, then cancer cells are killed, but severe side effects and toxicity occur due to affecting normal cells
Solution Approach 1:
The patent applies local quality by making the therapeutic effect specific to prostate cancer cells through PAX2 targeting. The system selectively induces DEFB1 expression only in PAX2-positive cancer cells, leaving normal cells unaffected. This spatial and cellular specificity resolves the contradiction by concentrating the therapeutic action where needed while sparing healthy tissue.
Solution Approach 2:
The patent uses PAX2 as an intermediary target and DEFB1 as a mediator to achieve selective cancer cell death. Rather than directly applying toxic agents to all cells, the system first targets PAX2 (which is overexpressed in prostate cancer), then activates DEFB1 as an intermediate step that leads to selective apoptosis. This multi-step intermediary approach enables discrimination between cancer and normal cells.
2Object-affected harmful factors
If DEFB1 expression is induced by inhibiting PAX2, then prostate cancer cells are selectively killed with minimal toxicity, but the mechanism requires specific molecular targeting
Solution Approach 1:
The patent employs self-service by utilizing the endogenous DEFB1 gene already present in the prostate cancer cell genome. Instead of introducing foreign therapeutic agents, the system activates the cell's own defense mechanism against itself. The PAX2 inhibition triggers the cell's pre-existing DEFB1 gene to produce antimicrobial peptides that kill the cancer cell, eliminating the need for complex external delivery systems.
Solution Approach 2:
The patent applies parameter changes by modifying the expression level of PAX2 (from high to low) to trigger a cascade that activates DEFB1. By changing the regulatory parameter of PAX2 expression, the system indirectly controls DEFB1 activation. This parameter-based control simplifies the mechanism compared to direct DEFB1 delivery, as it uses the cell's own regulatory networks.
Data Source
AI summary
Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.